Torben Straight Nissen

Torben Straight Nissen is an Executive Partner at Flagship Pioneering and the CEO of Repertoire Immune Medicines. In his role at Flagship, he contributes to the company’s strategic and operational objectives, including establishing its Preemptive Health and Medicine initiative and providing executive leadership to portfolio companies such as Rubius Therapeutics and Generate:Biomedicines. He currently serves on the board of Repertoire Immune Medicines and Flagship Labs 84.

Torben has provided executive and R&D leadership to biotech and pharmaceutical companies for more than 20 years. Prior to joining Flagship, Torben was at Pfizer where he headed up Strategic Portfolio Management for the company’s worldwide R&D organization. In this role, he oversaw ­­Pfizer’s portfolio, spanning from discovery to Phase 2b across Pfizer’s 300+ programs in all major therapeutic areas. Earlier in his career, Torben served as Chief Operating officer for Ascendis Pharma (Nasdaq: ASND) and Managing Director for Maxygen Inc.

Torben is a co-author or co-inventor of more than 100 publications and published patents. He holds a Ph.D. in molecular biology and biochemical engineering from the Technical University of Denmark and Carlsberg Laboratories and a Master of Science degree in chemical engineering from the Technical University of Denmark.